Use of evidence-based therapy for the secondary prevention of acute coronary syndromes in Malaysian practice

被引:9
|
作者
Kassab, Yaman Walid [1 ]
Hassan, Yahaya [2 ]
Abd Aziz, Noorizan [2 ]
Akram, Hadeer [1 ]
Ismail, Omar [3 ]
机构
[1] Univ Sains Malaysia, Sch Pharmaceut Sci, Dept Clin Pharm, George Town 11800, Malaysia
[2] Univ Teknol MARA, Dept Clin Pharm, Bandar Puncak Alam, Selangor, Malaysia
[3] Hosp Pulau Pinang, Dept Cardiol, George Town, Malaysia
关键词
acute coronary syndromes; evidence-based pharmacotherapy; secondary prevention; utilization; ST-SEGMENT ELEVATION; MYOCARDIAL-INFARCTION; MANAGEMENT; ASPIRIN; CARE;
D O I
10.1111/j.1365-2753.2012.01894.x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Rationale Despite the availability of various prevention guidelines on acute coronary syndrome (ACS), secondary prevention practice utilizing aspirin, beta-blockers, angiotensin converting enzyme inhibitors and statins still can be sub-optimal. Aims and objectives To review and document the utilization of pharmacotherapy for the secondary prevention of ACS in patients discharged from a Malaysian hospital. Methods A retrospective cross-sectional study was conducted at a tertiary hospital in Penang, Malaysia. Patients with a primary diagnosis of ACS were identified from medical records over a 4-month period. A range of clinical data was extracted from medical records, including medical history, clinical presentation and pharmacotherapy both on admission and at discharge. This audit focused on the use of four guideline-recommended therapies: aspirin +/- clopidogrel, beta-blockers, statins and angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blockers (ARBs). Results Data pertaining to a total of 380 ACS patients was extracted and reviewed, the mean age of the study population was 57.49 years and 73.9% of population was males. Patients with unstable angina accounted for 56.6% of the admissions whereas 23.4% and 20% of the patients were admitted for ST-elevation myocardial infarction and non-ST-segment elevation infarct respectively. 95.7% of the patients received antiplatelets comprising of at least aspirin, and 82% received aspirin plus clopidogrel. Furthermore, 80.3% of the patients received a beta-blocker at discharge, 95% a statin and 69.7% received either an ACEI or ARB. Compared with patients who presented with myocardial infarction (with or without ST-segment elevation), those presenting with unstable angina were less likely to receive the combination of aspirin plus clopidogrel or an ACEI/ARB at discharge. Patients over 65 years of age were also less likely to receive a beta-blocker at discharge, compared with younger patients. Conclusions There is a good adherence to evidence-based guidelines for the secondary prevention of ACS in this local setting. However, there is some potential underutilization in the older population and patients presenting with unstable angina.
引用
收藏
页码:658 / 663
页数:6
相关论文
共 50 条
  • [1] Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice
    Vermeer, N. S.
    Bajorek, B. V.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2008, 33 (06) : 591 - 601
  • [2] Evidence-based medical therapy of patients with acute coronary syndromes
    Ramanath, Vijay S.
    Eagle, Kim A.
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2007, 7 (02) : 95 - 116
  • [3] Evidence-Based Medical Therapy of Patients with Acute Coronary Syndromes
    Vijay S. Ramanath
    Kim A. Eagle
    [J]. American Journal of Cardiovascular Drugs, 2007, 7 : 95 - 116
  • [4] International variation in the use of evidence-based medicines for acute coronary syndromes
    Kramer, JM
    Newby, LK
    Chang, WC
    Simes, RJ
    Van de Werf, F
    Granger, CB
    Lee, KL
    White, HD
    Piegas, LS
    Topol, EJ
    Califf, RM
    Armstrong, PW
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 (23) : 2133 - 2141
  • [5] Persistence of combination of evidence-based medical therapy in patients with acute coronary syndromes
    Amar, Jacques
    Ferrieres, Jean
    Cambou, Jean-Pierre
    Amelineau, Elisabeth
    Danchin, Nicolas
    [J]. ARCHIVES OF CARDIOVASCULAR DISEASES, 2008, 101 (05) : 301 - 306
  • [6] Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome
    Fitchett, David H.
    Leiter, Lawrence A.
    Lin, Peter
    Pickering, Jennifer
    Welsh, Robert
    Stone, James
    Gregoire, Jean
    Mcfarlane, Philip
    Langer, Anatoly
    Gupta, Anil
    Goodman, Shaun G.
    [J]. CJC OPEN, 2020, 2 (05) : 402 - 415
  • [7] Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes
    Mukherjee, D
    Fang, JM
    Chetcuti, S
    Moscucci, M
    Kline-Rogers, E
    Eagle, KA
    [J]. CIRCULATION, 2004, 109 (06) : 745 - 749
  • [8] Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes
    Mukherjee, D
    Giri, K
    Fang, JM
    Chetcuti, S
    Moscucci, M
    Kline-Rogers, E
    Eagle, KA
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 298A - 298A
  • [9] Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations
    Fitchett, David H.
    Goodman, Shaun G.
    Leiter, Lawrence A.
    Lin, Peter
    Welsh, Robert
    Stone, James
    Gregoire, Jean
    Mcfarlane, Philip
    Langer, Anatoly
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2016, 32 (07) : S15 - S34
  • [10] Acute coronary syndromes - Management and secondary prevention
    Wenaweser, Peter
    Windecker, Stephan
    [J]. HERZ, 2008, 33 (01) : 25 - +